Pharsight

Drugs that contain Rolapitant Hydrochloride

1. Varubi patents expiration

VARUBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7049230 TERSERA Method of forming a contact plug in a semiconductor device
Dec, 2023

(5 months ago)

US8178550 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Apr, 2027

(2 years from now)

US7049320 TERSERA NK1 antagonists
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists
Dec, 2022

(1 year, 5 months ago)

US8404702 TERSERA Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)

US7981905 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)

US7563801 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)

US8470842 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Jan, 2029

(4 years from now)

US8361500 TERSERA Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
Oct, 2029

(5 years from now)

US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 01, 2020

NCE-1 date: 02 September, 2019

Market Authorisation Date: 25 October, 2017

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS; TABLET;ORAL

More Information on Dosage

VARUBI family patents

Family Patents